SCHEMBL1346100

SCHEMBL1346100

C[C@@H](C(=O)O)c1ccccc1Oc1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 2/20 0.52
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
XIAP P98170 1/20 0.45
PTGS1 P23219 2/20 0.44
PTGS2 P35354 1/20 0.44
CAMK2A Q9UQM7 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 2/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
FABP4 P15090 2/20 0.40
FABP5 Q01469 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11833301 1.00 CXCL8 (0.52) CXCL8AKR1C3AKR1C2XIAPPTGS1
SCHEMBL3628494 0.88 CXCL8 (0.54) CXCL8AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL1345130 0.88 CXCL8 (0.54) CXCL8AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL3630480 0.88 CXCL8 (0.54) CXCL8AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL11094201 0.87 CXCL8 (0.50) CXCL8AKR1C3AKR1C2XIAPPTGS1
SCHEMBL11124056 0.86 CXCL8 (0.49) CXCL8AKR1C3AKR1C2XIAPPTGS1
SCHEMBL1344836 0.84 XIAP (0.46) CXCL8XIAPCAMK2AKMT2AMEN1
SCHEMBL1345669 0.81 PTGS1 (0.54) CXCL8PTGS1PTGS2KMT2AMEN1
SCHEMBL8875079 0.81 PTGS1 (0.54) CXCL8PTGS1PTGS2KMT2AMEN1
SCHEMBL3817959 0.81 PTGS1 (0.54) CXCL8PTGS1PTGS2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2229942-B1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPE SPA (IT) 2012-08-29 EP disclosed
US-8063242-B2 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion DOMPE PHA.R.MA S.P.A. (IT) 2011-11-22 US disclosed
EP-2229942-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them Dompe S.p.A. (IT) 2010-09-22 EP disclosed
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPÉ FARMACEUTICI S.P.A. (IT) 2005-02-17 US disclosed
EP-1455773-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2004-09-15 EP disclosed
WO-2003043625-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them CXCR2, FPR1, CCR2 CXCL8 16/4885AKR1C3 767/4885AKR1C2 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.